Feb. 23, 2010 /PRNewswire-FirstCall/ — Cephalon, Inc. (Nasdaq: CEPH) announced today that it has exercised its option to acquire Ception Therapeutics, Inc., following receipt of positive data from a clinical study in adults with eosinophilic asthma. A Phase II clinical trial of …
Trending at Lumira Ventures
Pharmasset Announces Complete Enrollment of RG7128 Phase 2b Clinical Study
Learn More-External Link
Cardiovascular Systems Completes Enrollment In CALCIUM 360° Clinical Trial
Study Evaluates Clinical Benefits of Treating Peripheral Arterial Disease Behind and Below the Knee with Diamondback 360(R) System ST. PAUL, Minn., Apr 29, 2010 (BUSINESS WIRE) –Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), has completed patient enrollment in its prospective, randomized CALCIUM …
Pharmasset Prices Underwritten Offering of Common Stock
Learn More-External Link
Pharmasset Initiates Phase 2a Trial with PSI-7977, a Chirally Pure Isomer of PSI-7851
Learn More-External Link
Minnesota’s Cardiovascular Systems gets FDA approval for Phase 2 coronary trial
Learn More-External Link
Lumira portfolio company SkinStore.com Agrees to be Acquired by drugstore.com, inc.
BELLEVUE, Wash., Dec. 28, 2009 (GLOBE NEWSWIRE) — drugstore.com, inc. (Nasdaq:DSCM – News), a leading online retailer of health, beauty, vision, and pharmacy products that owns and operates the Beauty.com(TM) webstore, today announced that it has entered into an agreement …
Stenum Hospital First to offer M6 Artificial Lumbar Disc Replacement Surgery
Learn More-External Link
Resonant Medical to Exhibit Clarity System at Premier Radiation Oncology Conference
Learn More-External Link
KAI Reports Positive Preclinical Results in Pain Therapeutic Program Targeting Gamma PKC Pathway
Learn More-External Link
Alexza to Raise $19.7 Million in Private Placement
Learn More-External Link
Cardiovascular Systems Reports Two-Year Data Showing Durable Outcomes in Patients Treated with Diamondback 360° Pad System
September 22, 2009 11:00 AM Eastern Daylight Time ST. PAUL, Minn. & SAN FRANCISCO–(BUSINESS WIRE)–Two-year follow-up of patients in the first-ever prospective, multi-center clinical trial evaluating a plaque removal product show promising results after treatment with the Diamondback 360® PAD System, …